Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Lixte Biotechnology Holdings, Inc. (LIXT) had Income from Continuous Operations of $-6.01M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-6.08M |
|
-- |
|
-- |
|
$5.11M |
|
$-5.11M |
|
$-0.90M |
|
$-6.01M |
|
$-6.01M |
|
$-6.01M |
|
|
Income from Continuous Operations |
$-6.01M |
$-6.01M |
|
$-6.01M |
|
$-5.11M |
|
$-5.11M |
|
4.84M |
|
4.84M |
|
$-1.26 |
|
$-1.26 |
|
| Balance Sheet Financials | |
$5.18M |
|
-- |
|
$7.56M |
|
$12.73M |
|
$1.33M |
|
-- |
|
$0.44M |
|
$1.77M |
|
$9.23M |
|
$10.96M |
|
$10.96M |
|
8.79M |
|
| Cash Flow Statement Financials | |
$-3.07M |
|
$-3.17M |
|
$10.31M |
|
$1.04M |
|
$5.11M |
|
$4.07M |
|
$1.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-65.11% |
|
-54.83% |
|
-47.20% |
|
-54.83% |
|
$1.25 |
|
$-0.63 |
|
$-0.63 |
|